Regina Hodits

Managing Director at Angelini Ventures

Speaker

Regina is a Managing Director at Angelini Ventures. Prior to this role, she was the Managing Partner at Wellington Partners Life Sciences (WPLS) and represented the WPLS funds on the Boards of Minervax, Seamless, Sidekick Health, SNIPR Biome, and TRiCares. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / Boston Scientific), invested in Themis Medical (acquired by MSD). In addition, she serves on the Board of the BII BioInnovation Institute, is the Chairperson in of the Vienna university founders organization inits and is a member of the advisory group for KfW Capital and the SME council of the German Ministry of Economics BMWK.

Before this role, Regina led the European life sciences efforts of Boston-based Atlas Venture. She was the founding investor in Bicycle Therapeutics (NASDAQ: BCYC), F-star, and Jenavalve, and served on several Boards, including U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (became part of Horizon Pharma NASDAQ: HRZN), Shanghai-based Novamed, and has been an external director at GlaxoSmithKline’s Respiratory TA Board. Before, Regina worked for Apax Partners, and started to build her extensive network in the global healthcare industry during her tenure at McKinsey. In the 90s, Regina gained initial insights into the fast-growing biotech sector as post-doctoral researcher at the MRC Cambridge UK. Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry.